Care management of patients with high cardiovascular risk in Hungary an international and Hungarian longitudinal comparison of target level achievement by Jancsó, Zoltán et al.
RESEARCH ARTICLE Open Access
Care management of patients with high
cardiovascular risk in Hungary an
international and Hungarian longitudinal
comparison of target level achievement
Zoltán Jancsó1, Imre Rurik1, László Kolozsvári1, Lajos Mester2, Anna Nánási1, Csaba Oláh3, Tímea Ungvári1,
Katalin Vraukó TCs1, László Kalabay4 and Péter Torzsa4*
Abstract
Background: Patients with high cardiovascular risk are usually cared for in primary care settings. Assessment of the
effectiveness of long-time care was a subject of many European studies in the last two decades. This paper aims to
present two Hungarian primary care cross sectional surveys and to compare their results to the primary care arms
of the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) III.
and IV. studies.
Methods: Between 2010 and 2011, 679 patients with high cardiovascular risk were recruited in 20 Hungarian
primary care practices and 628 patients were selected in 40 practices between 2015 and 2016. The actual national
recommendations were used for classification, all based on European guidelines. Achievements of target levels for
blood pressure, total-, LDL-and HDL-cholesterols, triglyceride, and HbA1c (in diabetics) were recorded and analyzed.
Further cardiovascular risk factors, such as smoking, BMI, waist-circumference were also evaluated.
Results: There was a statistically significant improvement in the management of blood-pressure and plasma LDL-
cholesterol levels among high risk patients, while there was no change in the plasma triglyceride values. The
effectiveness of diabetes care deteriorated. In international relation, the management of blood pressure and plasma
LDL-cholesterol values were better in Hungary when compared to the results of EUROASPIRE III-IV. studies, while
the previous advantage in diabetes care disappeared. A higher proportion of diabetic patients was above the target
values in Hungary than the means of the European surveys. There was a higher proportion of smokers in the
Hungarian samples, while the proportion of obese and overweight patients was similar to the European sample.
Conclusions: Primary care has a unique role in cardiovascular prevention. Although many of the patients are
managed appropriately, there is a need to improve primary care services in Hungary, giving more competences to
GPs in prescription and introducing structural changes in the healthcare system.
Keywords: Cardiovascular risk, Cardiovascular prevention, Diabetes type 2, Dyslipidemia, EUROASPIRE, High risk
patients, Hungary, Hypertension, Primary care, Target level
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Background
Cardiovascular disease of atherosclerotic origin is among
the major causes of death and hospital admissions in
middle-aged and older people in Europe. Thus, primary
and secondary prevention of these morbidities is a top
priority of national public health policies in European
countries. During the last two decades various national
and international societies developed guidelines for
physicians in order to support their preventive and cura-
tive practice. The first European guideline of the Joint
European Task Force of the European Society of Cardi-
ology and Other Societies on Cardiovascular Disease Pre-
vention (JETF) was published in 1994 [1] but the real
breakthrough came in 2003 with the third guideline [2],
introducing the Systematic Coronary Risk Evaluation
(SCORE) method. The SCORE is based on European
epidemiological data, focused on global cardiovascular
risk, estimating the chance of fatal cardiovascular events
in the upcoming ten years. This guideline defined target
values for the management of major risk factors and
gave recommendations on lifestyle change and prevent-
ive medication. Currently the sixth recommendation of
the JETF [3] is applicable, published in 2016.
Assessment of the success of the implementation of
the guidelines and the effectiveness of the continuous
care of patients with high cardiovascular risk was the
subject of several European studies in the past two de-
cades. The European Action on Secondary and Primary
Prevention by Intervention to Reduce Events (EUROAS-
PIRE-I) survey started in the middle of the 90s, followed
by others, involving 12 and 14 European countries. The
last EUROASPIRE studies were conducted in 2006–2007
(III.) and in 2014–2015 (IV) respectively, and both of
them had primary care arms [4, 5]. In these cross-
sectional surveys the study populations were high risk
patients without an established cardiovascular disease.
Lifestyle (eating habits, physical activity and smoking),
BMI, blood pressure and metabolic parameters (plasma
lipids, glucose) were recorded and compared to the tar-
get values of the relevant JETF guidelines [2, 6]. There
were limited national publications about what happened
in primary care settings and Hungary has not been
invited to participate in these studies, although some na-
tional surveys were conducted on primary and secondary
prevention during this period. Regarding the target
values of lipid parameters, the Hungarian REALITY and
Multi-GAP studies concluded that the effectiveness of
outpatient clinics of lipid specialists or cardiologists was sig-
nificantly higher than that in primary care, but these differ-
ences have gradually diminished over the years [7–9].
The national” Hungarian Cardiovascular Consensus
Conferences” (HCCC) are organized biannually, where
opinion leaders of cardiovascular and metabolic diseases
discuss and share their experiences. They are followed
by the publication of updated guidelines, which are
almost identical to the European guidelines of Task
Forces [6, 10–12].
We conducted two nationwide cross-sectional surveys
to assess the efficacy of cardiovascular risk management
in respect of the achievement of target values of some
anthropometric, clinical and laboratory parameters in
different subgroups of high risk patients in Hungarian
primary care. The first survey was performed in 2010–
2011, the next one in 2015–2016. In this report our aim
was to make two comparisons. The first, between our
two surveys referred to above – to follow the changes in
efficacy in Hungarian risk management -, and the sec-
ond, between the results of our surveys and the data of
the subpopulation of the relevant European surveys – to
compare our results to, i.e. the outcomes of primary pre-
vention arms of EUROASPIRE III. and IV. studies, per-
formed almost at the same time as our surveys [4, 5].
The Hungarian primary health care system is mainly
based on solo practices, where one GP and one practice
nurse work, and in some cases there is one more assist-
ant. It’s an old and fragmented structure with limited
possibilities and resources for patient education and life-
style management, without real cooperation between the
practices and other stakeholders in providing primary
and secondary prevention (e.g. health improvement of-
fices, local governments etc.) This situation results in a
huge gap between possibilities and needs regarding pre-
ventive activities in primary care.
Nowadays there are governmental initiatives in Hungary
to create general practice partnerships involving more
healthcare professionals and higher resources to support
the general risk assessment of patients and risk manage-
ment activities.
Methods
Our study group - based on the Hungarian primary care
research network - performed a representative nation-
wide cross-sectional survey in 2010–2011. It was re-
peated in 2015–2016 using almost the same method
while taking into account the updates of the national
and international guidelines.
Followed by an advertisement for targeted – mostly
tutorial – practices, the applicant practices were selected
by location and the population they served.
Twenty primary care practices participated in the first
survey and 40 in the second one. There were minimal
overlaps between the practices, which covered the whole
country geographically. Half of the practices were in
urban settings, the other half in rural areas.
Patients between 40 and 80 years of age were included
to whom one or more of the following medications had
been prescribed at least for 12 months before enrollment
into the survey: (1) antihypertensive and/or (2) lipid
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lowering and/or (3) antidiabetic medication. The first 10
persons who visited the primary care office were con-
secutively selected from each diagnostic (prescription)
group. Exclusion criteria were: (1) the available elec-
tronic health records were incomplete, (2) participation
in our former survey.
All measurements were retrieved from the electronic
medical records for each patient, which were: (1) mean
values of the last three blood pressure (BP) measurements,
(2) laboratory data of fasting values of plasma glucose,
HbA1c, triglycerides, total, HDL and LDL-cholesterols, based
on calculation and (3) anthropometric parameters [13].
Risk assessments were done centrally by the research
group according to the IV. and VI. Guidelines of the Hun-
garian Cardiovascular Consensus Conferences (Table 1)
[11, 12]. The principal assessment criteria of these guide-
lines were essentially identical to those of the IV. and V.
JETF guidelines [6, 10].
Statistical analysis was performed on the relevant data
of the two Hungarian surveys by using Student’s un-
paired t-test. The level of significance was set to P < 0.05.
All analyses were performed using the STATA 10.1.
software (Statacorp LP. College Station, TX, USA).
Data were stored under the provisions of the Hungarian
national health data protection law. According to recent
Hungarian regulations, no permission of an ethical com-
mittee was required because all data were drawn from pa-
tients’ files and were anonymously sent to the data
processing center.
All health care providers contributed on a voluntary
basis, without any financial incentives.
Results
Table 2 presents the data of the two Hungarian surveys
(2010–2011 and 2015–2016). Sample size and mean
values were very similar. Patients with high risk but free
from cardiovascular disease (subgroups A and D),
reached the target blood pressure in 75.8 and 60%, re-
spectively, which is a significant difference. In the first
survey only 37.1 and 30.1% of the patients were below
the target threshold (subgroups B and C). This rate was
42.7% in the identical subgroup (E) during the second
survey, while the target value had changed from 130/80
mmHg to 140/90 mmHg. Only 33.3% of the patients
reached the LDL-cholesterol target value (< 2.5 mmol/l)
in the first survey, while five years later it increased to
Table 1 Cardiovascular risk classifications according to the relevant Hungarian guidelines [11, 12]
2009 2015
Very high risk: Very high risk:
• Coronary heart disease +
o Diabetes mellitus (type 2 or type 1 with micro-
or macroalbuminuria) or
o Metabolic syndrome or
o Smoking
• Atherosclerotic coronary, cerebrovascular or peripheral artery disease
• Acute coronary syndrome, ischemic stroke, critical limb ischemia
• SCORE≥ 10%/10 years
• Diabetes mellitus (type 1 or 2) and≥ 1 further major risk factor and/or
target organ damage
• Severe chronic kidney disease (eGFR < 30 ml/min/1.73 m2 and proteinuria)
• Familiar hypercholesterolaemiaHigh risk (with CVD or equivalent):
• Atherosclerotic coronary, cerebrovascular or
peripheral artery disease
• Diabetes mellitus (type 2 or type 1 with micro- or
macroalbuminuria)
• Chronic kidney disease
High risk without cardiovascular disease: High risk:
Subclinical atherosclerosis:
Atherosclerotic plaque (proven by ultrasound/CT/MRI)
without clinical symptoms
Ankle-brachial index ≤0.9
Presence of at least one of these serious risk factors:
• Total cholesterol > 8.0 mmol/l
• BP > 180/110mmHg
• BMI > 40 kg/m2
• eGFR < 60 ml/min
• Micro- or macroalbuminuria, proteinuria
• Premature cardiovascular event in close relatives
(men: < 55 ys, women: < 65 ys)
• Left ventricular hypertrophy
• SCORE: ≥5% /10 ys
• Metabolic syndrome
• Atherosclerotic plaque (proven by ultrasound/ CT/MRI) without clinical
symptoms
• Ankle-brachial index ≤0.9
• Diabetes mellitus (type 1 or 2) without further major risk factors
• Chronic kidney disease (eGFR: 30–60 ml/min/1.73 m2 and/or proteinuria)
• Premature cardiovascular event in close relatives (men: < 55 ys, women:
< 65 ys)
• BP > 180/110mmHg
• Atherogenous dyslipidemia
• BMI > 40 kg/m2
• Metabolic syndrome
• SCORE: ≥5 < 10%/10 ys
Medium risk: SCORE: 2–4%/10 ys
Low risk: SCORE: 0–1%/10 ys
Abbreviations: BMI body mass index, eGFR estimated glomerular filtration rate, CT computer tomography, CVD cardiovascular disease, MR magnetic resonance
imaging, RR blood pressure, SCORE systematic coronary risk evaluation
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39.3%. Just over 10% of patients reached the LDL-
cholesterol target value (< 1.8 mmol/l) in the first and
15.8% in the second survey, the difference is significant.
Reaching the 1.7 mmol/l plasma triglyceride target value
was more successful in subgroups B and C. Achievement
of the HDL-cholesterol target value improved slightly by
the second survey, it was between 64 and 71% in all
subgroups.
In both surveys the glycated hemoglobin (HbA1c) tar-
get values were analyzed only among type 2 diabetic pa-
tients. During the five-year period, there were no
improvements in Hungary. The proportion of patients
with HbA1c < 7% was 42% in the first and 40% in our
second survey, respectively.
Table 3 compares the main findings of the Hungarian
surveys to the European studies performed in the same
time-period. The measurement of total cholesterol was
later replaced by plasma LDL-cholesterol, therefore
these values were compared. It was found that the treat-
ment of hypertensive patients was always more effective
in Hungary. Total cholesterol levels were almost identi-
cal, while LDL-cholesterol level was treated more effect-
ively in Hungarian primary care. Considering only the
HbA1c values, the advantage of the Hungarian patients
Table 2 Distribution of the Hungarian study populations by categories, by achievement of target values, based on effective national
guidelines [11, 12]
Study period 2010–2011 2015–2016
National guideline launched 2009 2015
Total study population (N) 679 628
By genders (N) Male: 320 Female:359 Male: 312 Female:316
≤60 years 141 133 119 92
> 60 years 179 226 193 224
Average age [years±SD] 62.3 ± 11.5 62.7 ± 10.8
Years under treatment, means [±SD] 8.7 ± 6.4 10.2 ± 7.4
BMI > 25 kg/m2 [%] 81.8 83.9
BMI > 30 kg/m2[%] 40.6 44.4
waist circumference
(men: > 102 cm, women: > 88 cm) [%]
64.3 62.0
Smoking [%] 21.6 21.0
STUDY SUBGROUPS STUDY SUBGROUPS
A B C D E
Subgroups by risk ASY HR-CVD VHR HR VHR
BLOOD PRESSURE
Target value [mmHg] < 140/90 < 130/80 < 130/80 < 140/90 DM: < 140/85
Nephropathy+proteinuria: < 130/80
Proportion of patients on target [%] 75.8* 37.1 30.1 60.0* 42.7
LDL-CHOLESTEROL
Target value [mmol/l] < 3.0 < 2.5 < 1.8 < 2.5 < 1.8
Proportion of patients on target [%] 47.5 33.3 10.7* 39.3 15.8*
TRIGLICERIDE
Target value [mmol/l] < 1.7 < 1.7
Proportion of patients on target [%] 38.5 55.2 42.1 47.8 45.0
HDL-CHOLESTEROL
Target value [mmol/l] > 1.0 (male) > 1.3 (female) > 1.0 (male) > 1.3 (female)
Proportion of patients on target [%] 71.6 65.6 64.1 66.7 68.0
DIABETES
Target value [HbA1c [%] < 7.0 < 7.0
Proportion of patients on target [%] 42.0 40.0
Abbreviations: ASY Asymptomatic high risk patient; DM diabetes mellitus; HR High risk patients, HR-CVD High risk patients with CVD; VHR Very high risk patients;
*: Significant (p < 0.05) difference between the marked subgroups in the same row
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disappeared, five years later the EUROASPIRE data were
better [4, 5]. Statistical differences between the Hungar-
ian and European results could not be calculated be-
cause of the lack of detailed European datasets.
Discussion
Main findings
There was a significant improvement in Hungary in the
management of blood-pressure and LDL-cholesterol
level among high risk patients. The effectiveness of dia-
betes care deteriorated.
In international relation, management of blood pres-
sure and LDL-cholesterol values were better in Hungary,
while previous advantage in diabetes care disappeared.
Higher ratio of diabetic patients was above the target la-
boratory values in Hungary than the means of the
EUROPEAN survey, with no respective national data
available from the participating countries.
Other comparisons were made according to the main
risk factors and registered laboratory parameters regard-
ing target levels.
Study population
The Hungarian study population was geographically rep-
resentative, more patients were involved in the surveys
than in other European countries (109 the lowest, 519
the highest), the mean age was 1–2 years higher [4, 5].
Smoking
The rate of current Hungarian smokers did not change
significantly in the high-risk populations (21.6% vs.
21.0%). This ratio is lower than the value of the total
adult Hungarian population (29%), but higher than the
European average of general population (16.6%) [5, 14].
Obesity (BMI and waist circumference)
There was an apparent increase in the proportion of
overweight (BMI above 25 kg/m2: 81.8% vs. 84.3%) and
obese people (BMI over 30 kg/m2: 40.6% vs. 44.4%).
However, this failed to reach statistical significance.
The European survey provided similar findings [5].
The situation is just slightly better regarding waist cir-
cumference. The increase in body weight towards patho-
logical levels is described as a real threat to the
population of Hungary [15, 16]. Unhealthy nutritional
habits and the sedentary lifestyle are considered as the
main factors responsible [17, 18]. An international com-
parison has revealed that the situation is not better in
Europe, either. The primary care data of EUROASPIRE
IV. found that 83.4% of the study populations of the 14
European countries had a BMI over 25 kg/m2 [5]. Im-
portant international recommendations focus on the
prevention of obesity in primary care recommending
changes in lifestyle and nutrition [3, 19]. This could also
be realistic in Hungary, as proven by a previous pilot
project within the initiatives of managed care [20].
Table 3 Comparison of the laboratory results of subgroups of high-risk patients without CVD in the Hungarian surveys in primary
care and European surveys with arms in general practice, study fields, effective guidelines
Ist survey
(marked with A in Table 2.)
EUROASPIRE III. IInd survey
(marked with D in Table 2.)
EUROASPIRE IV.
Study period 2010–2011 2006–2007 2015–2016 2014–2015
Study field Hungary 12 European countries Hungary 14 European countries
Base of risk assessment Fourth Joint European Task Force Guideline Fifth Joint European Task Force Guideline
Risk level High-risk without CVD High-risk without CVD
BLOOD PRESSURE




Patients on target [%] 75.8 36.1 60.0 44.7
TOTAL-CHOLESTEROL
Target value [mmol/l] < 5.0 < 5.0
Patients on target [%] 33.9 33.7
LDL-CHOLESTEROL
Target value [mmol/l] < 2.5 < 2.5
Patients on target [%] 39.3 32.7
Risk level High risk DM patients without CVD
HbA1c
Target value [%] < 7 < 7 < 7 < 7
Patients on target [%] 48.8 39.9 43.0 58.5
Abbreviations: CVD cardiovascular disease, DM diabetes mellitus
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At the time of the first survey, there were yet three
subgroups of high-risk patients (asymptomatic, high risk
with cardiovascular disease and very high risk) but only
two (high risk and very high risk) at the second evalu-
ation due to the changes of risk classification in the
guideline of the VI. Hungarian Cardiovascular Consen-
sus Conference [12]. In accordance with the EUROAS-
PIRE III. and IV. primary prevention arms [4, 5], these
results were compared to the values of our surveys’ high
risk subgroups free from cardiovascular diseases.
Blood pressure
In all surveys, the Hungarian achievements were better
than the European ones; 75.8% vs. 36.1% [4], and 60% vs.
44.7% [5]. The ratio of appropriately treated hypertensive
patients decreased significantly (from 75.8 to 60.0%)
within the subgroups free from cardiovascular diseases (A
and D, in Table 2), but improved (to 42.7%) in subgroups
with cardiovascular disease or with very high risk (B, C
and E, in Table 2). The latter improvement could be ex-
plained with the higher recommended threshold (130/80
vs. 140/90mmHg) [12]. In our previous study focusing
only on hypertension, the target value achievement was
more favorable than the European results [9].
Plasma lipid parameters
In the earlier studies - when only total-cholesterol levels
were compared - Hungarian data (33.9%) were almost
the same as the European ones (33.7%) [4]. Regarding
LDL-cholesterol, the target value achievements improved
significantly in all relevant subgroups. The success rate
changed from 33.3 to 39.3% in the high-risk subgroup
(target: ≤ 2.5 mmol/l), and from 10.7 to 15.8% in the very
high-risk subgroup (target: ≤ 1.8 mmol/l), respectively,
the latter being statistically significant (p < 0.05). The tar-
get level achievement in the high-risk subgroup was bet-
ter than in the latest European survey (39.3% vs. 32.7%)
[5]. These results indicate that “lipid-management” is
not appropriate in either Europe or in Hungary.
Within the subgroups, the success rates by triglyceride
were between 38 and 55%, and in case of HDL-choles-
terol they were between 64 and 72% without significant
changes over the five–year period. Primary care exami-
nations of EUROASPIRE III. and IV. did not report de-
tailed European data of these lipid parameters.
Diabetes care (type 2)
In European comparison - in subgroups without CVD -,
data of our first survey were better than the European
average (48.8% vs. 39.9%), but this advantage disap-
peared within five years and the trend turned worse
(43% vs. 58.5%) [4, 5].
There is a wide variety of available therapeutic options
in primary care settings. All newest and evidence-based
medications can be prescribed in Hungary, although
GPs have less competence in prescribing some innova-
tive and expensive drugs, mainly in diabetes care. The
compliance and adherence of patients are often bad, par-
tially explaining the therapeutic failures. Better results in
the achievement of blood pressure target values and
worse efficacy in performing the target values in lipid-
lowering and antidiabetic therapy can be partly ex-
plained by the need of deep lifestyle changes in the treat-
ment of type-2 diabetes and the bad statin adherence of
patients with dyslipidemia [21, 22]. To improve lifestyle
modification and drug adherence we need more human
resources and capacities in primary care.
Solo practices dominate in Hungary, i.e. usually one
doctor works with one nurse. One of the possible ways for
professional improvement could be the cooperation be-
tween practices, supported by other health care workers,
e.g., dietitian, physiotherapists, health-psychologist or
more practice nurses. In this field, a short-term pilot pro-
ject has been introduced in Hungary [23]. According to
the pilot’s results there are new governmental initiatives to
support general practice partnerships to be formed where
preventive services (health promotion, risk assessment,
lifestyle modification, patient education etc.) can be pro-
vided in a wider range with higher resources, involving
much more healthcare professionals and service providers
in a cooperative way. It can result in an improvement in
patients’ health behavior, lifestyle changes and adherence
to therapies, overall in the reduction of cardiovascular risk.
Our conclusions are in line with those of the EUROAS-
PIRE IV. primary care arm study in European context [5].
Study limitation
The comparison of different, perhaps not representative
populations in different countries, at different times,
with different competences at primary care level could
be the most important limitations of our study. How-
ever, the goals and methods used in the management of
patients with high cardiovascular risk are based on com-
mon European guidelines.
The criteria systems referring to subgroup classifica-
tion and the number of subgroups have been changed in
the previous decade [11]. In some categories, the target
values were also modified. These changes made the ana-
lyses more difficult, but we tried to compare the results
of the most similar subgroups in both Hungarian and
international respects.
The international overview could be the strength of
this study and the achievements of the Hungarian GPs
are ready for international comparison.
Conclusions
Primary care has a unique role in cardiovascular preven-
tion in each European country. The effectiveness of
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cardiovascular risk management in Hungary did not im-
prove essentially during the period between 2010 and
2016. Family physicians should be helped by updated
education on more effective methods in patients’ educa-
tion and lifestyle intervention with an approach of co-
operative management in general practice partnership
settings. They need more support with the involvement
of other health care professionals, wider community
orientation and expanded competencies. Medical advice
against smoking, inappropriate nutritional habits, seden-
tary lifestyle and obesity should be promoted both in the
general population and at governmental levels.
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